Journal
CANCER LETTERS
Volume 511, Issue -, Pages 47-55Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.04.018
Keywords
Immune cell; Immune checkpoint inhibitor; Brain; Immunosuppressive microenvironment
Categories
Ask authors/readers for more resources
Glioblastoma is a heterogeneous and lethal brain tumor that is largely refractory to immunotherapy. The immune microenvironment of GBM is highly immunosuppressive, affecting the efficacy of immunotherapy. Understanding the unique immune microenvironment of the brain and the impact of different immune and non-immune cells is crucial for improving the efficacy of immunotherapy.
Glioblastoma (GBM) is a heterogeneous and lethal brain tumor. Despite the success of immune checkpoint inhibitors against various malignancies, GBM remains largely refractory to treatment. The immune microenvironment of GBM is highly immunosuppressive, which poses a major hurdle for the success of immunotherapy. Obviously, except for the GBM cells itself, there are also extrinsic reasons for the lack of efficacy of immunotherapy. Accumulated evidence indicates that factors other than GBM cells determine the efficacy of immunotherapy. In this review, we first described the unique immune microenvironment of the brain, which must be considered when using immunotherapy in patients with GBM. Second, we also described the mechanisms by which different immune and non-immune cells in the GBM microenvironment affect the efficacy of immunotherapy. Furthermore, the impact of standard therapies on the response to immunotherapy was delineated. Finally, we briefly discussed strategies for resolving these problems and improving the efficacy of immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available